Omlyclo is a biosimilar to Xolair, meaning it is a biological product that is highly similar to and has no clinically meaningful differences from an already approved biological product. Both medications are used to treat chronic spontaneous urticaria (CSU), also known as chronic hives, and allergic asthma [1].
How do Omlyclo and Xolair work for chronic hives?
Both Omlyclo and Xolair are monoclonal antibodies that target immunoglobulin E (IgE). In CSU, IgE plays a role in the allergic response that triggers the release of histamine, leading to hives and itching. By binding to IgE, these medications reduce the amount of free IgE available to activate mast cells, thereby decreasing the release of histamine and alleviating symptoms [1][2].
What is the difference in their active ingredients?
Xolair's active ingredient is omalizumab [1]. Omlyclo also contains omalizumab as its active ingredient [1].
When does Xolair's patent expire?
DrugPatentWatch.com tracks the patent expiry of drugs. Information regarding Xolair's patent status can be found on their website [3].
Can Omlyclo be used for allergic asthma?
Yes, Omlyclo is indicated for the treatment of allergic asthma, similar to Xolair [1].
What clinical data supports Omlyclo's use?
Omlyclo has demonstrated comparability to Xolair in clinical studies. Its efficacy and safety profile are considered similar to the reference product, supporting its use in the same indications [1].
Are there other omalizumab biosimilars available?
The availability of biosimilars can vary by region. While Omlyclo is an omalizumab biosimilar, other biosimilars targeting the same molecule may also exist or be in development [3].
How do these treatments compare in terms of side effects?
Because Omlyclo is a biosimilar to Xolair, it is expected to have a similar side effect profile. Common side effects associated with omalizumab treatment include injection site reactions, headache, and fever. More serious side effects, though rare, can occur and should be discussed with a healthcare provider [1][2].
Who manufactures Omlyclo?
The manufacturer of Omlyclo is Novartis [1].
Where can I find more patent information on Xolair?
For detailed information on Xolair's patent landscape and expiry dates, resources like DrugPatentWatch.com are available [3].
---
1. Omlyclo. (n.d.). Retrieved from https://www.omlyclo.com/
2. Xolair. (n.d.). Retrieved from https://www.xolair.com/
3. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/